| Originator: |
|
DHSC & NHS England and Improvement: Supply disruption alert
|
|
|
|
- Care Trusts
- Mental Health Trusts
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Specialists Trusts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- Learning Disabilities Trusts
- Mental Health & Social Care Trusts
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- Ambulance Trusts
- Special Health Authorities
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Mental Health & Learning Disabilities Trusts
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- Acute Trusts
- Community Trusts
- NHS Trusts (England) - Chief Executive
- DHSC Supply Disruption - Medicines
|
| Title: |
|
Propofol emulsion for infusion and injection (all strengths) - Supply Disruption Update
|
| Broadcast content: |
|
This
alert contains up to date information following the much-improved supply
picture of all strengths of propofol emulsion for infusion and injection and
supersedes SDA/2021/002 (issued on 03 February).
Given the links to Covid-19 we have sent this alert to a broader mailing list than would usually receive a Supply Disruption Alert of this type.
Please note that no response is required via the CAS website to this alert.
|
| Additional information: |
|
This alert is not relevant to Primary Care.
|